Reproductive Anatomy and Physiology
Testicular Architecture
- Seminiferous tubules: Site of spermatogenesis; contain Sertoli cells and developing germ cells
- Leydig cells: Located in interstitial tissue; produce testosterone
- Sertoli cells: "Nurse cells" that support developing sperm; create blood-testis barrier
- Epididymis: Site of sperm maturation and storage (2-3 weeks)
Spermatogenesis Timeline
The complete cycle of sperm production takes approximately 74 days (range: 64-75 days):³
- Spermatogonia → Spermatocytes (mitotic division)
- Spermatocytes → Spermatids (meiotic division)
- Spermatids → Spermatozoa (spermiogenesis)
- Epididymal transit: Additional 10-14 days for maturation
Clinical implication: Any intervention affecting spermatogenesis (lifestyle changes, medications, or cessation of suppressive agents) requires at least 3 months before meaningful changes can be assessed in semen analysis.
Key Hormones in Male Fertility
| Hormone | Normal Range | Role in Fertility |
|---|
| FSH | 1.5-12.4 mIU/mL | Direct driver of spermatogenesis |
| LH | 1.7-8.6 mIU/mL | Stimulates testosterone production |
| Total Testosterone | 300-1000 ng/dL | Supports Sertoli cell function |
| Intratesticular Testosterone | 50-100x serum | Required for spermatogenesis |
| Inhibin B | 80-400 pg/mL | Marker of Sertoli cell/spermatogenic function |
| Estradiol | 10-40 pg/mL | Elevated levels can impair spermatogenesis |
| Prolactin | 4-15 ng/mL | Elevated levels suppress GnRH |
Semen Analysis Interpretation
WHO 6th Edition Reference Values (2021)
The World Health Organization released updated semen analysis reference values in 2021, representing the 5th percentile of fertile men.⁴ Values below these thresholds suggest potential fertility impairment but do not guarantee infertility:
| Parameter | WHO 6th Edition (2021) | Clinical Notes |
|---|
| Volume | ≥1.4 mL | Low volume: ejaculatory duct obstruction, retrograde ejaculation |
| Sperm Concentration | ≥16 million/mL | <15 million = oligozoospermia |
| Total Sperm Count | ≥39 million/ejaculate | Total number more predictive than concentration alone |
| Total Motility | ≥42% | Includes progressive + non-progressive |
| Progressive Motility | ≥30% | Grade A + B combined |
| Vitality | ≥54% live | Important if motility <40% |
| Morphology | ≥4% normal forms | Strict Kruger criteria |
| pH | 7.2-8.0 | Low pH may indicate ejaculatory duct obstruction |
Motility Classification (WHO 6th Edition)
The 6th edition reintroduced four-category motility classification:⁴
- Grade A (Fast Progressive): ≥25 μm/sec at 37°C
- Grade B (Slow Progressive): 5-25 μm/sec
- Grade C (Non-Progressive): <5 μm/sec, no forward progression
- Grade D (Immotile): No movement
Common Semen Analysis Abnormalities
| Term | Definition | Common Causes |
|---|
| Oligozoospermia | <16 million sperm/mL | Varicocele, hormonal, genetic |
| Asthenozoospermia | <42% total motility | Varicocele, infection, anti-sperm antibodies |
| Teratozoospermia | <4% normal morphology | Often idiopathic; varicocele, toxins |
| Azoospermia | No sperm in ejaculate | Obstructive or non-obstructive |
| Oligoasthenoteratozoospermia (OAT) | All three abnormal | Most common finding in infertile men |
| Cryptozoospermia | Rare sperm found only after centrifugation | Better prognosis than azoospermia |
Semen Analysis Protocol
- Abstinence period: 2-7 days (WHO recommendation); 2-3 days optimal
- Collection: Masturbation preferred; complete sample collection critical
- Analysis timing: Within 1 hour of collection
- Repeat testing: At least 2 samples, 2-4 weeks apart, if first abnormal
- Interpretation: Must correlate with clinical history and physical exam
Causes of Male Infertility
Pre-Testicular Causes (Hormonal)
Hypogonadotropic Hypogonadism (Low FSH/LH):
- Kallmann syndrome (congenital GnRH deficiency + anosmia)
- Pituitary adenomas
- Hyperprolactinemia
- Exogenous testosterone/anabolic steroids
- Opioid-induced hypogonadism
- Severe obesity
- Chronic illness
Treatment: Generally excellent prognosis with gonadotropin therapy (hCG + FSH)
Testicular Causes (Primary)
| Cause | Prevalence | Key Features |
|---|
| Varicocele | 35-40% of infertile men | Most common treatable cause |
| Cryptorchidism | History in 3-5% | Even if corrected, reduced fertility |
| Genetic | 10-15% | Klinefelter (47,XXY), Y-microdeletions, CFTR mutations |
| Infections | 6-10% | Orchitis (mumps), epididymitis |
| Testicular torsion | History variable | Ischemic damage |
| Chemotherapy/Radiation | Dose-dependent | Alkylating agents most gonadotoxic |
| Idiopathic | 30-40% | No identifiable cause despite workup |
Post-Testicular Causes (Obstructive/Functional)
- Ejaculatory duct obstruction: Low volume, acidic pH, absent fructose
- Vas deferens obstruction: Prior vasectomy, CBAVD (CFTR mutation)
- Retrograde ejaculation: Post-ejaculatory urinalysis shows sperm
- Ejaculatory dysfunction: Anorgasmia, anejaculation (neurological causes)
Azoospermia Classification
| Type | FSH Level | Testicular Size | Cause |
|---|
| Obstructive (OA) | Normal | Normal | Vas/epididymal/ejaculatory duct obstruction |
| Non-obstructive (NOA) | Usually elevated | Often small | Testicular failure (genetic, idiopathic) |
Varicocele
Overview
Varicocele—abnormal dilation of the pampiniform plexus—is the most common identifiable and surgically correctable cause of male infertility.⁵ Present in 15% of the general male population but found in 35-40% of men with primary infertility and up to 80% of men with secondary infertility.
Pathophysiology
- Venous reflux → increased scrotal temperature (+1-2°C)
- Oxidative stress → sperm DNA damage
- Hypoxia → impaired spermatogenesis
- Hormonal effects → may reduce intratesticular testosterone
Grading
| Grade | Clinical Findings |
|---|
| Subclinical | Not palpable; detected only on ultrasound |
| Grade I | Palpable only with Valsalva maneuver |
| Grade II | Palpable without Valsalva |
| Grade III | Visible through scrotal skin |
Indications for Repair
Per AUA/ASRM guidelines, varicocele repair is indicated when:
- Palpable varicocele (Grades I-III)
- Infertility documented or couple attempting pregnancy
- Abnormal semen parameters
- Female partner has normal fertility or correctable infertility
Surgical Options
| Technique | Success Rate | Recurrence | Complications |
|---|
| Microsurgical subinguinal | Highest | <1% | Lowest hydrocele risk |
| Laparoscopic | Good | 3-5% | Risk of visceral injury |
| Open inguinal/retroperitoneal | Good | 5-15% | Higher recurrence |
| Percutaneous embolization | Variable | 10-15% | Alternative for poor surgical candidates |
Fertility Outcomes After Repair
Recent meta-analyses demonstrate significant benefits:⁵
- Pregnancy rate: OR 1.82 (95% CI: 1.37-2.41) compared to no repair
- Live birth rate: OR 2.17 (95% CI: 1.55-3.06) in IVF cycles with prior repair
- Sperm concentration: Improvement of 9-12 million/mL
- Motility: Improvement of 10-12%
- DNA fragmentation: Significant reduction
Timeline: Expect improvement in semen parameters at 3-6 months post-repair; maximal benefit often seen at 6-12 months.
Testosterone and Fertility: A Critical Distinction
The Paradox
- Testosterone is essential for libido, erections, and general well-being
- Testosterone is essential within the testicle for spermatogenesis
- Exogenous testosterone suppresses spermatogenesis by eliminating the FSH/LH signal
Mechanism of TRT-Induced Infertility
- Exogenous testosterone raises serum T levels
- Hypothalamus detects elevated T → suppresses GnRH
- Pituitary receives less GnRH → reduced FSH and LH secretion
- Without LH → Leydig cells reduce testosterone production
- Intratesticular testosterone drops by ~94%²
- Without adequate intratesticular T + FSH → spermatogenesis fails
- Result: Oligozoospermia or azoospermia
Key Point
TRT is NOT male contraception. While most men become severely oligospermic or azoospermic on TRT, suppression is not reliable enough for contraception. Some men maintain sufficient sperm for pregnancy.
Recovery After TRT Discontinuation
Recovery rates from the literature:⁶
| Time After Discontinuation | Recovery to 20 million/mL |
|---|
| 6 months | 67% |
| 12 months | 90% |
| 16 months | 96% |
| 24 months | ~100% |
Factors affecting recovery:⁶
- Age: Older men recover more slowly
- Duration of TRT: Longer use = slower recovery
- Baseline function: Cryptozoospermia recovers faster than azoospermia
- Formulation: IM testosterone: 3.1 months average; transdermal: 7.4 months average
Fertility Preservation Strategies
Pre-TRT Considerations
Before starting TRT, all men of reproductive age should:
- Be counseled on fertility implications
- Have baseline semen analysis
- Consider sperm cryopreservation (banking)
- Discuss alternatives if fertility desired
Concurrent Therapy: hCG with TRT
Human chorionic gonadotropin (hCG) mimics LH and maintains intratesticular testosterone:²
| Protocol | Dosing | Effect |
|---|
| Fertility preservation | 500 IU SC every other day | Maintains intratesticular T; preserves spermatogenesis |
| Testicular size maintenance | 250 IU SC every other day | Prevents atrophy; may preserve some spermatogenesis |
| Higher dose option | 1000-1500 IU 2-3x weekly | For men with poor response to lower doses |
Key evidence: In men on TRT, intratesticular testosterone drops 94% without hCG. With 250 IU hCG EOD, the drop is only 7%; with 500 IU EOD, intratesticular T actually increases 26%.²
Limitations: ~33% of men (especially older, longer TRT duration) may not maintain adequate spermatogenesis with hCG alone and may require FSH addition.
Selective Estrogen Receptor Modulators (SERMs)
Clomiphene Citrate
| Aspect | Details |
|---|
| Mechanism | Blocks hypothalamic estrogen receptors → increases GnRH → increases FSH/LH |
| Dosing | 25-50 mg daily or every other day |
| Testosterone effect | Increases total T by 200-400 ng/dL typically |
| Sperm parameters | Concentration +8.4 million/mL; Motility +8.1% |
| Pregnancy rate | ~17% (range 0-40%) in clinical trials |
| Advantages | Oral, inexpensive, maintains/improves fertility |
| FDA status | Off-label for male infertility |
Enclomiphene (pure zuclomiphene isomer):
- More potent at raising gonadotropins
- Greater improvement in total motile sperm count vs. clomiphene
- Not yet FDA-approved; available through some compounding pharmacies
Gonadotropin Therapy
For Hypogonadotropic Hypogonadism or Recovery After TRT:
| Phase | Treatment | Duration |
|---|
| Initial | hCG 1500-3000 IU 2-3x weekly | 3-6 months |
| Add FSH if needed | FSH 75-150 IU 3x weekly | Additional 3-6 months |
| Maintenance | Adjust based on response | Ongoing |
Expected outcomes: 70% achieve sperm counts sufficient for IUI within 12 months of medical therapy.
Aromatase Inhibitors
Anastrozole (off-label):
- Blocks testosterone → estradiol conversion
- Useful when estradiol elevated (>40-50 pg/mL)
- Typical dose: 0.5-1 mg twice weekly
- May improve T:E2 ratio and sperm parameters in obese men
Diagnostic Workup
History Focus Points
- Reproductive history: Prior pregnancies, time trying to conceive
- Sexual history: Frequency, timing, erectile/ejaculatory function
- Medical history: Cryptorchidism, infections, surgeries, cancer treatment
- Medications: TRT, anabolic steroids, 5-alpha reductase inhibitors, SSRIs, opioids
- Lifestyle: Smoking, alcohol, heat exposure, occupation
- Family history: Cystic fibrosis, infertility, genetic disorders
Physical Examination
| Finding | Clinical Significance |
|---|
| Testicular size | <15 mL suggests impaired spermatogenesis |
| Testicular consistency | Soft = atrophy; firm nodule = tumor |
| Varicocele | "Bag of worms" on standing; increases with Valsalva |
| Vas deferens | Absence suggests CFTR mutation |
| Epididymis | Fullness/tenderness suggests obstruction or infection |
| Secondary sex characteristics | Eunuchoid proportions, gynecomastia suggest hypogonadism |
Laboratory Evaluation
Initial Panel:
- Semen analysis (x2 if abnormal)
- Total testosterone (morning)
- FSH
Extended Panel (if initial abnormal):
- Free testosterone
- LH
- Prolactin
- Estradiol
- TSH
- Inhibin B (specialized, not always available)
Interpretation
| Pattern | FSH | LH | T | Diagnosis |
|---|
| Low/Normal | Low | Low | Low | Hypogonadotropic hypogonadism |
| High | Normal/High | Low/Normal | Primary testicular failure |
| Normal | Normal | Normal | Obstructive azoospermia or idiopathic |
Imaging
- Scrotal ultrasound: Testicular size, varicocele, masses, epididymal abnormalities
- Transrectal ultrasound: Ejaculatory duct obstruction, seminal vesicle abnormalities
Genetic Testing
| Test | Indication | Finding |
|---|
| Karyotype | NOA with small testes, azoospermia | Klinefelter (47,XXY) in 10-15% |
| Y-microdeletion | NOA or severe oligospermia (<5 million/mL) | AZFa/b = no sperm retrieval; AZFc = 50-70% retrieval |
| CFTR mutation | CBAVD, low volume, absent vas | Increased CF carrier risk for offspring |
Post-Ejaculatory Urinalysis
Indicated when low ejaculate volume (<1.4 mL) with normal hormones:
- Sperm in urine confirms retrograde ejaculation
- Treatment: Sympathomimetics, bladder neck procedures, or sperm harvest from urine
Treatment Options
Lifestyle Modifications (Evidence-Based)
| Intervention | Evidence | Recommendation |
|---|
| Weight loss | Strong | BMI >30 associated with lower T, impaired spermatogenesis |
| Smoking cessation | Strong | Reduces sperm count 13-17%, motility 10% |
| Limit alcohol | Moderate | >14 drinks/week impairs spermatogenesis |
| Avoid heat | Moderate | Hot tubs, saunas, laptop on lap raise scrotal temperature |
| Exercise | Moderate | Improves T; avoid excessive endurance training |
| Reduce cannabis | Moderate | Associated with reduced sperm count and morphology |
Medical Therapy
| Indication | First-Line | Second-Line |
|---|
| Hypogonadotropic hypogonadism | hCG + FSH | Pulsatile GnRH (rarely available) |
| Idiopathic OAT | Clomiphene or empiric antioxidants | hCG + FSH |
| TRT-induced suppression | Discontinue TRT + hCG ± SERM | hCG + FSH |
| Elevated estradiol | Anastrozole | Weight loss |
| Hyperprolactinemia | Cabergoline or bromocriptine | Surgical if macroadenoma |
Surgical Options
| Procedure | Indication | Success |
|---|
| Varicocelectomy | Palpable varicocele + abnormal SA | 60-70% improvement in SA |
| Vasectomy reversal | Prior vasectomy | 70-95% patency; pregnancy depends on interval |
| TURED | Ejaculatory duct obstruction | 50-75% improvement |
| Micro-TESE | Non-obstructive azoospermia | 50-60% sperm retrieval |
Assisted Reproductive Technologies
| Technique | Sperm Requirement | Indication |
|---|
| Timed intercourse | Normal SA | Unexplained, mild male factor |
| IUI | >5-10 million motile sperm | Mild-moderate male factor |
| IVF | >100,000 motile sperm | Moderate male factor, tubal factor |
| ICSI | Single sperm per egg | Severe male factor, azoospermia with retrieval |
| TESE/micro-TESE | Testicular extraction | Azoospermia |
Environmental and Lifestyle Factors
Heat Exposure
- Scrotal temperature 2-4°C below core body temperature is optimal
- +1-2°C elevation impairs spermatogenesis
- Sources: Hot tubs, saunas, laptops, prolonged sitting, fever
Occupational Exposures
| Exposure | Effect | Occupations at Risk |
|---|
| Heavy metals (lead, cadmium) | Reduced count, motility | Battery workers, painters |
| Pesticides | Hormonal disruption | Agricultural workers |
| Solvents | DNA damage | Painters, dry cleaners |
| Radiation | Dose-dependent suppression | Healthcare, nuclear workers |
| Heat | Impaired spermatogenesis | Bakers, welders, drivers |
Medications Affecting Fertility
| Medication Class | Effect | Reversibility |
|---|
| Testosterone/AAS | Suppresses spermatogenesis | Yes, 6-24 months |
| 5-alpha reductase inhibitors | Variable, possible long-term | Usually yes |
| SSRIs | Possible reduction in parameters | Yes |
| Opioids | Suppresses GnRH | Yes, with cessation |
| Sulfasalazine | Oligospermia | Yes |
| Chemotherapy | Dose-dependent, may be permanent | Variable |
Supplements: Evidence Assessment
| Supplement | Evidence Level | Notes |
|---|
| Zinc | Moderate (if deficient) | 30 mg daily; most benefit in deficient men |
| Folate/Folic acid | Mixed | May reduce DNA fragmentation |
| Coenzyme Q10 | Limited positive | Antioxidant; 200-400 mg daily |
| L-carnitine | Limited positive | May improve motility |
| Vitamin C/E | Limited | Antioxidant effects |
| Ashwagandha | Limited | May improve count and motility |
Bottom line: Antioxidant supplementation may provide modest benefit in idiopathic male infertility, but evidence remains limited. No supplement substitutes for addressing modifiable factors or medical/surgical treatment of identified causes.
Sperm Quality Changes with Age
Unlike women, men do not have a clear "reproductive endpoint," but sperm quality does decline:⁸
| Parameter | Change with Age |
|---|
| Semen volume | Decreases 0.15-0.5% per year after age 35 |
| Sperm concentration | May decrease modestly |
| Motility | Decreases 0.6-0.8% per year after 40 |
| Morphology | Decreases 0.2-0.9% per year |
| DNA fragmentation | Increases significantly after 35-40 |
Clinical Implications
- Time to pregnancy: Increases with paternal age (>40 years)
- Miscarriage risk: Higher with advanced paternal age
- ART outcomes: DNA fragmentation may impact embryo quality
- But: Effect less pronounced than maternal age effects
Offspring Risks with Advanced Paternal Age
Accumulating evidence suggests increased risks:⁸
| Condition | Association |
|---|
| De novo point mutations | Increase ~2 per year with paternal age |
| Autism spectrum disorder | Relative risk 1.5-2x with fathers >40-50 |
| Schizophrenia | Increased risk with advanced paternal age |
| Achondroplasia | Almost exclusively paternal origin |
| Rare single-gene disorders | Higher frequency |
Context: Absolute risks remain low; most children of older fathers are healthy. However, the relative increase is real and should be part of family planning discussions.
Special Populations
Hypogonadal Men Seeking Fertility
- Do not start TRT if fertility is desired in near term
- First-line: Clomiphene citrate or gonadotropins (hCG ± FSH)
- Advantages: Improves testosterone AND maintains/enhances spermatogenesis
Men on TRT Wanting Children
Options:
- Stop TRT + medical therapy: hCG + SERM; expect 3-12 months to recover
- Add hCG to TRT: May preserve spermatogenesis in some men
- Switch to clomiphene: Maintains testosterone, improves fertility
- Sperm banking: If prior to starting or while some sperm present
Cancer Survivors
- Pre-treatment banking: Standard of care when feasible
- Post-treatment: May take 2-5 years for recovery if it occurs
- Options for azoospermia: Micro-TESE may retrieve sperm in some cases
- Donor sperm: Alternative if no sperm retrievable
Azoospermic Patients
| Type | FSH | Approach | Sperm Retrieval Rate |
|---|
| Obstructive | Normal | TESE, PESA, or reconstruction | >95% |
| Non-obstructive | Elevated | Micro-TESE | 50-60% overall |
| NOA with AZFa/b deletion | Elevated | Donor sperm (no retrieval expected) | ~0% |
| NOA with AZFc deletion | Elevated | Micro-TESE | 50-70% |
References
- Agarwal A, Mulgund A, Hamada A, Chyatte MR. A unique view on male infertility around the globe. Reprod Biol Endocrinol. 2015;13:37. doi:10.1186/s12958-015-0032-1
- Coviello AD, Matsumoto AM, Bremner WJ, et al. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J Clin Endocrinol Metab. 2005;90(5):2595-2602. doi:10.1210/jc.2004-0802
- Heller CG, Clermont Y. Kinetics of the germinal epithelium in man. Recent Prog Horm Res. 1964;20:545-575.
- World Health Organization. WHO laboratory manual for the examination and processing of human semen. 6th ed. Geneva: World Health Organization; 2021.
- Birowo P, Rahendra Wijaya J, Atmoko W, Rasyid N. The benefits of varicocele repair for achieving pregnancy in male infertility: A systematic review and meta-analysis. Heliyon. 2020;6(11):e05439. doi:10.1016/j.heliyon.2020.e05439
- Kohn TP, Louis MR, Pickett SM, et al. Age and duration of testosterone therapy predict time to return of sperm count after human chorionic gonadotropin therapy. Fertil Steril. 2017;107(2):351-357.e1. doi:10.1016/j.fertnstert.2016.10.004
- Huijben M, Lock MT, de Kemp VF, et al. Clomiphene citrate for male infertility: A systematic review and meta-analysis. Andrology. 2023;11(5):987-996. doi:10.1111/andr.13388
- Sharma R, Agarwal A, Rohra VK, Assidi M, Abu-Elmagd M, Turki RF. Effects of increased paternal age on sperm quality, reproductive outcome and associated epigenetic risks to offspring. Reprod Biol Endocrinol. 2015;13:35. doi:10.1186/s12958-015-0028-x
Medical Disclaimer: This educational brief is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before starting any new health regimen. Individual results may vary. The information presented reflects current research as of January 2026 and may be updated as new evidence becomes available.